Capillary leak syndrome cost-effectiveness of therapy
Capillary leak syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Capillary leak syndrome cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Capillary leak syndrome cost-effectiveness of therapy |
FDA on Capillary leak syndrome cost-effectiveness of therapy |
CDC on Capillary leak syndrome cost-effectiveness of therapy |
Capillary leak syndrome cost-effectiveness of therapy in the news |
Blogs on Capillary leak syndrome cost-effectiveness of therapy |
Risk calculators and risk factors for Capillary leak syndrome cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: M. Hassan, M.B.B.S
Overview
Cost-effective therapy
Treatment | Mechanism of Action |
---|---|
Endothelial signal transduction | |
Bevacizumab |
|
Epoprostenol |
|
Theophylline + Terbutaline |
|
Immune modulation | |
Corticosteroids | |
Infliximab | |
IVIG | |
Plasmapheresis |
References
- ↑ "Bevacizumab Wins Cost-Effectiveness Contest in First-Line Metastatic Colorectal Cancer". Am Health Drug Benefits. 8 (Spec Issue): 10–2. 2015. PMC 4570073. PMID 26380601.
- ↑ Petros AJ, Turner SC, Nunn AJ (1995). "Cost implications of using inhaled nitric oxide compared with epoprostenol for pulmonary hypertension". J Pharm Technol. 11 (4): 163–6. doi:10.1177/875512259501100409. PMID 10144080.
- ↑ Jubran A, Gross N, Ramsdell J, Simonian R, Schuttenhelm K, Sax M; et al. (1993). "Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. A three-center study". Chest. 103 (3): 678–84. doi:10.1378/chest.103.3.678. PMID 8449051.
- ↑ Hayes E, Moroz L, Pizzi L, Baxter J (2007). "A cost decision analysis of 4 tocolytic drugs". Am J Obstet Gynecol. 197 (4): 383.e1–6. doi:10.1016/j.ajog.2007.06.052. PMID 17904969.